diabetic macular edema
Conditions
Interventions
None listed
Sponsors
Fukui university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with a diagnosis of diabetic macular edema Patients who started treatment with brolucizumab
Exclusion criteria
Exclusion criteria: Patients with hypersensitivity to drugs such as allergies Pregnant women, patients who may be pregnant, breastfeeding patients, and those who wish to become pregnant while in a research institution Patients who have participated in other clinical studies within 4 months Other patients who are judged by the principal investigator to be unsuitable as research subjects Patients with or suspected infection in or around the eye Patients with active intraocular inflammation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flare levels before administration of brolucizumab, 1 week after the first administration, 6 weeks after the first administration, and every 6 weeks after the second injection until the end of the induction period. | — |
Countries
Japan
Contacts
Public ContactYushi Ichihashi
Fukui university Ophthalmology
Outcome results
None listed